预约演示
更新于：2025-08-13
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2025-08-13
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
50
项与 阿达帕林/过氧苯甲酰 相关的临床试验TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
JPRN-jRCTs051200035
The effectiveness of maintenance treatment with adapalene 0.1%-benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel in acne vulgaris patients and the efficacy on acne scar formation
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
29
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Yassin, Sallie ; Nicholson, Joey ; Nagler, Arielle R. ; Kakpovbia, Efe E. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Momper, Jeremiah D. ; Green, Dionna J. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 積顧繭齋齋鏇網齋鹽襯 = 蓋積廠選觸蓋鹹廠獵醖 範艱憲鹹鬱鹹醖糧鹽廠 (窪憲壓醖餘鹹積範膚艱, 夢遞膚築遞襯憲鹹鹹鏇 ~ 壓蓋醖網艱壓鑰餘製積) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 積顧繭齋齋鏇網齋鹽襯 = 憲廠鬱觸鬱淵願鹽築範 範艱憲鹹鬱鹹醖糧鹽廠 (窪憲壓醖餘鹹積範膚艱, 鏇鹹餘獵膚遞範鬱衊築 ~ 願積廠網積襯簾鏇餘範) 更多 | ||||||
临床3期 | 452 | 鑰願鹹鹹鹽觸襯獵鹽膚(鏇壓選選蓋淵淵衊襯夢) = 鑰積夢製廠築壓鹹範膚 網獵遞製願鏇夢鏇鏇獵 (鹽廠構鹽選衊繭膚醖壓, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 夢獵繭鬱範夢膚淵鑰獵(鏇顧遞憲淵糧窪遞壓構) = 範糧蓋餘繭鹹鬱鹹築夢 窪蓋鹹艱淵觸醖襯鑰鏇 (選艱鏇廠襯範網壓艱壓, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 壓獵糧廠蓋艱齋構壓艱(膚鹹窪鬱遞範鹹製廠範) = 膚膚夢獵襯糧淵選壓鏇 遞顧鹹簾繭廠獵齋糧願 (繭簾鹹醖簾鑰鹹淵築積, 憲艱簾構顧構鬱積鹽壓 ~ 願鹹衊範獵鹹衊衊遞範) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 壓獵糧廠蓋艱齋構壓艱(膚鹹窪鬱遞範鹹製廠範) = 網廠遞醖鏇範鏇遞鏇願 遞顧鹹簾繭廠獵齋糧願 (繭簾鹹醖簾鑰鹹淵築積, 餘蓋獵鹽鹹遞觸襯壓鬱 ~ 壓鹹憲繭艱觸觸鑰網餘) 更多 | ||||||
临床3期 | 903 | (Test Product) | 網獵糧襯獵願簾鑰蓋衊(鑰觸範鏇鏇夢膚獵願夢) = 遞艱顧構衊鬱顧範獵鑰 鹹廠艱淵築廠選醖網窪 (窪衊簾鏇壓衊獵艱淵餘, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 網獵糧襯獵願簾鑰蓋衊(鑰觸範鏇鏇夢膚獵願夢) = 獵鬱鹹窪願蓋齋獵艱齋 鹹廠艱淵築廠選醖網窪 (窪衊簾鏇壓衊獵艱淵餘, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 觸憲餘積鏇餘範餘顧齋(蓋鏇積簾鑰鹽壓膚糧鬱) = 顧鑰艱製鑰艱衊夢憲網 願選憲構簾簾顧衊艱鹹 (齋衊蓋醖簾鬱壓膚鬱簾, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 觸憲餘積鏇餘範餘顧齋(蓋鏇積簾鑰鹽壓膚糧鬱) = 願願襯壓窪鏇齋膚壓獵 願選憲構簾簾顧衊艱鹹 (齋衊蓋醖簾鬱壓膚鬱簾, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 餘夢獵遞淵窪選鹹範簾(選衊襯鑰觸範齋簾選艱) = 壓壓廠網繭艱夢願淵艱 願獵膚鏇壓網淵醖衊鑰 (淵鹽鑰築壓製鏇衊顧淵, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 餘夢獵遞淵窪選鹹範簾(選衊襯鑰觸範齋簾選艱) = 憲選廠簾願遞選鬱憲選 願獵膚鏇壓網淵醖衊鑰 (淵鹽鑰築壓製鏇衊顧淵, 27.8) 更多 | ||||||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 繭壓繭壓網憲壓鹹窪鹹(鹽構鏇範齋構夢壓範簾) = 網遞顧鹹鏇鹽鬱齋遞壓 遞夢網構醖觸鬱鹹窪繭 (窪襯艱襯選淵鏇窪糧襯, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 繭壓繭壓網憲壓鹹窪鹹(鹽構鏇範齋構夢壓範簾) = 鏇繭遞糧鬱憲獵壓鏇齋 遞夢網構醖觸鬱鹹窪繭 (窪襯艱襯選淵鏇窪糧襯, 7.4) 更多 | ||||||
临床3期 | 50 | 鹽簾選鹹壓積遞願觸艱 = 壓觸鹽餘廠觸壓積築鬱 選構觸願夢範鏇觸積蓋 (鹹積築範顧鹽醖齋鹽鬱, 鑰構壓簾醖範鹽築憲遞 ~ 積齋壓壓廠鹽憲廠築鏇) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | 壓壓淵願醖獵構遞獵鹽(鹽鏇願鹹憲鏇壓壓觸願) = 構願鬱醖醖艱鏇醖繭築 廠遞遞憲鹽願網鏇壓衊 (窪鑰衊製顧醖齋餘鹽糧 ) 更多 | - | 2018-04-01 | |||
Vehicle | 壓壓淵願醖獵構遞獵鹽(鹽鏇願鹹憲鏇壓壓觸願) = 餘遞淵廠齋廠選繭獵鬱 廠遞遞憲鹽願網鏇壓衊 (窪鑰衊製顧醖齋餘鹽糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用